NEW OPPORTUNITIES FOR INVESTORS IN THE GROWING WOMEN'S SPORTS SECTOR July 2024 REPORT NEW OPPORTUNITIES FOR INVESTORS IN THE GROWING WOMEN'S SPORTS SECTOR Investment in women's sports has undergone a significant transformation in recent years, with the once underinvested market now commanding attention from sports fans and investors globally. The shift not only reflects the sector's growing economic potential, but also aligns with broader societal movements toward gender equality and diversity.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jeffrey Gargano
Taking Advantage of the New Purple Book Patent Requirements for Biologics | JD Supra
New federal legislation will take effect this year that will require a reference product sponsor to submit to the FDA a list of any patents identified to a biosimilar applicant during the patent dance. The FDA is required to list these patents in the Purple Book.
Organon Delaware Infringment
The District Court for the District of Delaware found Forest Labs’ patent for sublingual or buccal compositions of asenapine and methods of using such compositions to treat mental disorders, including schizophrenia and mania, infringed and not invalid. Forest Labs., LLC v. Sigmapharm Labs., LLC, et al., Civ. No. 16-cv-914 RGA, (D. Del. June 30, 2017) (Robinson, J.).
Unknown Problem Plus Nonobvious Solution Cannot Render Patent for Sublingual Formulation of Asenapine Obvious
The District Court for the District of Delaware found Forest Labs’ patent for sublingual or buccal compositions of asenapine and methods of using such compositions to treat mental disorders, including schizophrenia and mania, infringed and not invalid. Forest Labs., LLC v. Sigmapharm Labs., LLC, et al., Civ. No. 16-cv-914 RGA, (D. Del. June 30, 2017) (Robinson, J.).
Supply and Purchase Agreement Triggers On-Sale Bar Provision of 35 USC ยง 102(b)
The US Court of Appeals for the Federal Circuit reversed the district court and found that a Supply and Purchase Agreement between Helsinn and third-party MGI Pharma, Inc. (MGI) before the critical date of the asserted patents constituted a sale of the claimed invention. The court concluded that, after the Leahy-Smith America Invents Act (AIA), the details of the invention need not be publicly disclosed in the terms of sale.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jeffrey
Contact Jeffrey, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack